

VitroGel® Glioblastoma (GBM) Xeno-Free EMT Kit

Ready-to-use kit for 3D GBM tumoroid formation, supporting epithelial-to-mesenchymal transition and enabling long-term tumoroid culture.

Protocol
Catalog #: VHM08-K

Revision No: 1.0
Revision Date: 11/2025

www.thewellbio.com
support@thewellbio.com

US TF: +1 866.3D. CELLS
TEL: +1 973.855.4955

For research use only. Not intended for use in diagnostics or therapeutic procedures.



Scan the QR code

to access the latest product updates and resources.

thewellbio.com/product/vitrogel-glioblastoma-xeno-free-emt-kit/

Developing a glioblastoma multiforme (GBM) tumoroid model with VitroGel® GBM Xeno-Free EMT Kit



A. Introduction

Highly aggressive tumors, such as GBM, undergo epithelial-to-mesenchymal transition (EMT), a process in which cells shift from an epithelial to a mesenchymal phenotype, allowing extravasation from the primary site, invasion, and metastasis to other organs. To better evaluate EMT and other cancer-associated pathways, it is crucial to develop preclinical models that more accurately mimic the physiological tumor microenvironment. Tumoroids, as three-dimensional (3D) tumor models, have emerged as a powerful platform for preclinical studies due to their ability to recapitulate the tumor microenvironment compared to traditional two-dimensional (2D) models.

The **VitroGel® Glioblastoma (GBM) Xeno-Free EMT Kit** is an excellent tool for 3D GBM tumoroid generation that enables the cells to undergo the epithelial-to-mesenchymal transition for the examination of pathways involved in cancer metastasis, allowing drug screening and automation applications. The product kit features the ready-to-use and synthetic **VitroGel® EMT hydrogel** system in combination with the **RocketCell™ GBM Xeno-Free EMT supplement (50X)** and **VitroPrime™ Ultra-Low Attachment Plate, U-Bottom, 96-Well plate**. The VitroGel® Glioblastoma (GBM) Xeno-Free EMT Kit is designed to induce tumoroid formation from a simple single spheroid within the first two weeks, depending on the cell line used. This tool generates a biologically relevant and well-organized tumoroid model for studying tumor progression, EMT dynamics, and therapeutic response in a preclinical setting.

B. Contents

VitroGel® Glioblastoma (GBM) Xeno-Free EMT Kit (Catalog No. VHM08-K)

Components	Catalog No.	Size
VitroGel® EMT hydrogel	VHM08S	2 mL
RocketCell™ GBM Xeno-Free EMT supplement (50X)	RC05-S50	5 mL
VitroPrime™ Ultra-Low Attachment Plate, U-bottom, 96-well plate	VP-ULA96U	96-well

C. Storage and Stability of VitroGel® Glioblastoma (GBM) Xeno-Free EMT Kit components.

Upon receipt, store the VitroGel® EMT Hydrogel at 4°C for long-term stability.

The RocketCell™ GBM Xeno-Free EMT Supplement (50X) should be stored at -20°C or below. If needed, aliquot the supplement and store the portions at -20°C or below. Avoid repeated freeze-thaw cycles. Once thawed, the supplement remains stable for up to 2 weeks at 4°C.

Storage and Stability:

Product	Temperature	Time
VitroGel® EMT hydrogel	2°C-8°C	1 year
RocketCell™ GBM Xeno-Free EMT supplement (50X)	2°C-8°C; in the dark -80°C to -20°C	2 weeks 1 year
VitroPrime™ Ultra-Low Attachment Plate, U-bottom, 96-well plate	room temperature (25°C)	1 year

Epithelial-to-Mesenchymal Transition (EMT) GBM Tumoroid model

In this protocol, we use U87-MG cells as an example. The basal medium of choice needs to be adjusted based on selected cell type.

MATERIALS

- **VitroGel® Glioblastoma (GBM) Xeno-Free EMT Kit (Catalog No: VHM08-K)**
 - » VitroGel® EMT hydrogel (Catalog No: VHM08)
 - » RocketCell™ GBM Xeno-Free EMT supplement (50X) (Catalog No: RC05-S50)
 - » VitroPrime™ Ultra-Low Attachment Plate, U-bottom, 96-well plate (Catalog No: VP-ULA96U)
- GBM cells (e.g., U87-MG)
- Basal medium of choice (e.g., MEM medium for U87-MG cells)
- Micropipette; low retention pipette tips
- Centrifuge tubes or conical tubes

PROTOCOL

A. Medium preparation

1. Equilibrate the basal medium of choice and RocketCell™ GBM Xeno-Free EMT supplement (50X) to reach room temperature (25°C).

Note: Avoid freeze/thaw cycles of the RocketCell™ GBM Xeno-Free EMT supplement. If needed, we recommend aliquoting the supplement upon arrival.

2. Prepare complete cell culture medium by combining the basal medium of choice with 1X of the RocketCell™ GBM Xeno-Free EMT supplement.

Note: The complete cell culture medium is stable for 2 weeks at 4°C.

B. Spheroid Formation

1. Allow the complete cell culture medium with 1X RocketCell™ GBM Xeno-Free EMT supplement to reach room temperature, if prepared in advance.
2. Harvest GBM cells with TrypLE following standard procedures.
3. Prepare cell suspension in complete cell culture medium at a density of 1×10^6 cells/mL.
4. Add 20 μ L of cell suspension to the wells of the VitroPrime™ Ultra-Low Attachment Plate, U-bottom, 96-well plate.
5. Place the cultureware in the incubator at 37°C overnight to induce spheroid formation.

C. Tumoroid formation from GBM spheroids

1. Equilibrate the VitroGel® EMT hydrogel, RocketCell™ GBM Xeno-Free EMT supplement (50X), and complete cell culture medium to room temperature.
2. Assess spheroid formation with a microscope.
3. Combine VitroGel® EMT hydrogel with the RocketCell™ GBM Xeno-Free EMT supplement (50X) in a 1:1 v/v ratio.

For example: Mix 500 µL of hydrogel and 500 µL of supplement to have a total volume of 1000 µL mixture.

4. Gently add 40 µL of hydrogel-supplement mixture from step 3 to each well and incubate for 30 minutes at room temperature.

Important: Position the pipette tip close to the medium in the well when adding the hydrogel mixture to prevent shifting the spheroid from the center. Do not insert the pipette all the way into the well.

5. Add 100 µL of complete cell culture medium on top of the hydrogel and place the cultureware in the incubator at 37°C.
6. Remove and replenish 50% of the medium on top of the hydrogel from the cultures every 2-3 days and monitor the cultures with an inverted microscope to assess tumoroid formation.



Revision No: 1.1
Revision Date: 11/2025

For research use only. Not intended for use in diagnostics or therapeutic procedures.

THEWELL BIOSCIENCE INC. DISCLAIMS ALL WARRANTIES WITH RESPECT TO THIS DOCUMENT, EXPRESSED OR IMPLIED, INCLUDING BUT NOT LIMITED TO THOSE OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. TO THE FULLEST EXTENT ALLOWED BY LAW, IN NO EVENT SHALL THEWELL BIOSCIENCE INC BE LIABLE, WHETHER IN CONTRACT, TORT, WARRANTY, OR UNDER ANY STATUTE OR ON ANY OTHER BASIS FOR SPECIAL, INCIDENTAL, INDIRECT, PUNITIVE, MULTIPLE OR CONSEQUENTIAL DAMAGES IN CONNECTION WITH OR ARISING FROM THIS DOCUMENT, INCLUDING BUT NOT LIMITED TO THE USE THEREOF, WHETHER OR NOT FORESEEABLE AND WHETHER OR NOT THEWELL BIOSCIENCE INC. IS ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.

Terms and Conditions: thewellbio.com/terms-and-conditions/

TheWell Bioscience Inc.,
1 Deerpark Dr, Ste C Monmouth Junction, NJ 08852

www.thewellbio.com
support@thewellbio.com

US TF: +1 866.3D. CELLS
TEL: +1 973.855.4955

© 2025 TheWell Bioscience, Inc. All rights reserved. For research use only. Not intended for use in diagnostics or therapeutic procedures. VitroGel®, VitroINk®, Cyto3D®, CytoGrow™, RocketCell™, and VitroPrime™ are trademarks of TheWell Bioscience Inc. All other product names, logos, brands, trademarks, and registered trademarks are property of their respective owners.

TABLE OF CONTENTS

Introduction	3
2D Cell Culture Protocol	
2D Cell Culture Protocol #1 (example: NSC)	4
• 2D thin coating method using VitroGel® NEURON Hydrogel	4
• Case Study: Assessing the Growth of iPSC-Derived NSCs on 2D Coating of 1:200 Diluted VitroGel® NEURON in comparison to Geltrex	6
2D Cell Culture Protocol #2 (Example: B35 Cell Line)	9
• 2D “Blanket” Method for B35 Cell Line	9
• Immunofluorescence Protocol Performed After Using VitroGel® NEURON Hydrogel for Culturing Neurons via the “Blanket” Method	11
• Case Study #1 - Assessing Neuronal Differentiation Using the Hydrogel Covering “blanket” Method - Preparation of Hydrogel Mixture with Option A (Recommended)	13
• Case Study #2: Evaluating Neuronal Differentiation Using the Hydrogel Covering “Blanket” Method - Preparation of Hydrogel Mixture with Option B	15
3D Cell Culture Protocol	
3D Cell Culture Protocol #1 (Example: NSC)	17
• 3D NSC Culture with VitroGel® NEURON Hydrogel	17
• Case Study: 3D NSC Cultures Using VitroGel® NEURON	19
3D Cell Culture Protocol #2 (Example: B35 Cell Line)	22
• 3D B35 Culture with VitroGel® NEURON Hydrogel	22
Immunofluorescence Protocol for 3D Cultures	24
• Case Study: Immunofluorescence Protocol for 3D Cultures (Example: B35 Cell Line)	26

TABLE OF CONTENTS

Introduction	3
2D Cell Culture Protocol	
2D Cell Culture Protocol #1 (Example: NSC)	4
• 2D Thin Coating Method Using VitroGel® NEURON Hydrogel	4
Case Study:	
• Assessing the Growth of iPSC-Derived NSCs on 2D Coating of Diluted VitroGel® NEURON (1:200) in Comparison to Geltrex	6
2D Cell Culture Protocol #2 (Example: B35 Cell Line)	9
• 2D “Blanket” Method for B35 Cell Line	9
• Immunofluorescence Protocol Performed After Using VitroGel® NEURON Hydrogel for Culturing Neurons via the “Blanket” Method	11
Case Studies:	
• Assessing Neuronal Differentiation Using the Hydrogel Covering “Blanket” Method - Preparation of Hydrogel Mixture with Option A (Recommended)	13
• Evaluating Neuronal Differentiation Using the Hydrogel Covering “Blanket” Method - Preparation of Hydrogel Mixture with Option B	15
3D Cell Culture Protocol	
3D Cell Culture Protocol #1 (Example: NSC)	17
• 3D NSC Culture with VitroGel® NEURON Hydrogel	17
Case Study:	
• 3D NSC Cultures Using VitroGel® NEURON	19
3D Cell Culture Protocol #2 (Example: B35 Cell Line)	22
• 3D B35 Culture with VitroGel® NEURON Hydrogel	22
Immunofluorescence Protocol for 3D Cultures	24
Case Study:	
• Immunofluorescence Protocol for 3D Cultures (Example: B35 Cell Line)	26